Transitions in relabeling personalized medicine as precision medicine, precision health, or wellness genomics reflect shifting the locus of responsibility for health from individuals to clinicians and in shifting focus from genetic risk to genetic enhancement.
AMA J Ethics. 2018;20(9):E881-890. doi:
10.1001/amajethics.2018.881.
Shared decision making honors patient autonomy, particularly for preference-sensitive care decisions and even when patients have impaired decision-making capacity.
AMA J Ethics. 2020;22(5):E358-364. doi:
10.1001/amajethics.2020.358.
Jonathan Alhalel, Nicolás Francone, Sharon Post, Catherine A. O’Brian, PhD, and Melissa A. Simon, MD, MPH
Underrepresentation of individuals with limited English proficiency who speak Spanish is ongoing in phase 3 biomedical clinical trials and exacerbates health inequity.
AMA J Ethics. 2022;24(4):E319-325. doi:
10.1001/amajethics.2022.319.
Wandy D. Hernandez-Gordon, CD(DONA), BDT(DONA), CLC, CCE(ACBE)
CHWs’ work underscores need for clinicians and organizations to respond to deeply entrenched, long-standing patterns of oppression in ways that draw upon lived experience.
AMA J Ethics. 2022;24(4):E333-339. doi:
10.1001/amajethics.2022.333.
On this episode of Ethics Talk, Zahra H. Khan, Yoshiko Iwai, and Dr Sayantani DasGupta outline how “abolition medicine” can motivate critical responses to medicine’s expressions of hyper-punitive, deeply racialized exercises of state authority.